Skip to main content Accessibility help
×
Home

Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol

  • Robert B. Zipursky (a1), Hongbin Gu (a2), Alan I. Green (a3), Diana O. Perkins (a2), Mauricio F. Tohen (a4), Joseph P. McEvoy (a5), Stephen M. Strakowski (a6), Tonmoy Sharma (a7), René S. Kahn (a8), Raquel E. Gur (a9), Gary D. Tollefson (a4) and Jeffrey A. Lieberman (a10)...

Abstract

Background

Substantial weight gain is common with many atypical antipsychotics.

Aims

To evaluate the extent, time course and predictors of weight gain and its effect on study retention among people with first-episode psychosis treated with olanzapine or haloperidol.

Method

Survival analysis assessed time to potentially clinically significant weight gain (⩾7%) and the effect of weight gain on study retention. Weight gain during the 2-year study was summarised using last-observation-carried-forward (LOCF), observed cases and study completion approaches.

Results

After 2 years of treatment, LOCF mean weight gain was 10.2 kg (s.d.=10.1) for olanzapine (n=131) and 4.0 kg (s.d.=7.3) for haloperidol (n=132); observed cases mean weight gain was 15.4 kg (s.d.=10.0) for olanzapine and 7.5 kg (s.d.=9.2) for haloperidol. Change in body mass index was significantly predicted only by treatment group (P < 0.0001).

Conclusions

Olanzapine was associated with significantly greater weight gain than haloperidol, with both leading to greater weight gain than previously described.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol
      Available formats
      ×

Copyright

Corresponding author

Dr Robert B. Zipursky, Schizophrenia Programme, Centre for Addiction and Mental Health, 250 College Street, Toronto, Ontario, Canada M5T 1R8. Tel: +1 416 979 6913; fax: +1 416 979 4676; e-mail: robert_zipursky@camh.net

Footnotes

Hide All

Declaration of interest

This work was financially supported by Lilly Research Laboratories. M.F.T. and G.D.T. are employees of Lilly Research Laboratories.

Footnotes

References

Hide All
Allison, D. B. & Casey, D. E. (2001) Antipsychotic-induced weight gain: a review of the literature. Journal of Clinical Psychiatry, 62 (suppl. 7), 2231.
Allison, D. B., Mentore, J. L., Heo, M., et al (1999) Antipsychotic-induced weight gain: a comprehensive research synthesis. American Journal of Psychiatry, 156, 16861696.
American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders (4th edn) (DSM–IV). Washington, DC: APA.
Beasley, C. M. Jr, Hamilton, S. H., Crawford, A. M., et al (1997) Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. European Neuropsychopharmacology, 7, 125137.
Blin, O. & Micallef, J. (2001) Antipsychotic-associated weight gain and clinical outcome parameters. Journal of Clinical Psychiatry, 62 (suppl. 7), 1121.
Ganguli, R., Brar, J. S. & Ayrton, Z. (2001) Weight gain over 4 months in schizophrenia patients: a comparison of olanzapine and risperidone. Schizophrenia Research, 49, 261267.
Gupta, S., Droney, T., Al-Samarrai, S., et al (1999) Olanzapine: weight gain and therapeutic efficacy. Journal of Clinical Psychopharmacology, 19, 273275.
Kay, S. R., Opler, L. A. & Fiszbein, A. (1992) Positive and Negative Syndrome Scale (PANSS): Manual. New York: Multi-Health Systems, Inc.
Kinon, B. J., Basson, B. R., Gilmore, J. A., et al (2001) Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. Journal of Clinical Psychiatry, 62, 92100.
Lieberman, J. A., Tollefson, G., Tohen, M. D., et al (2003) Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized double-blind trial of olanzapine versus haloperidol. American Journal of Psychiatry, 160, 13961404.
Lindenmayer, J. P., Czobor, P., Volavka, J., et al (2003) Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. American Journal of Psychiatry, 160, 290296.
Newcomer, J. W., Haupt, D. W., Fucetola, R., et al (2002) Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Archives of General Psychiatry, 59, 337345.
Sachs, G. S. & Guille, C. (1999) Weight gain associated with use of psychotropic medications. Journal of Clinical Psychiatry, 60 (suppl. 21), 1619.
Sheitman, B. B., Bird, P. M., Binz, W., et al (1999) Olanzapine-induced elevation of plasma triglyceride levels. American Journal of Psychiatry, 156, 14711472.
Tollefson, G. D., Beasley, C. M., Tamura, R. N., et al (1997) Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine and haloperidol. American Journal of Psychiatry, 154, 12481254.
Wirshing, D. A. (2001) Adverse effects of atypical antipsychotics. Journal of Clinical Psychiatry, 62 (suppl. 21), 710.

Related content

Powered by UNSILO

Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol

  • Robert B. Zipursky (a1), Hongbin Gu (a2), Alan I. Green (a3), Diana O. Perkins (a2), Mauricio F. Tohen (a4), Joseph P. McEvoy (a5), Stephen M. Strakowski (a6), Tonmoy Sharma (a7), René S. Kahn (a8), Raquel E. Gur (a9), Gary D. Tollefson (a4) and Jeffrey A. Lieberman (a10)...

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed.